Robocath has announced the launch of a first-in-human (FIH) clinical study evaluating its new robotic system in coronary artery disease.
The study will recruit 20 patients with coronary artery disease, primarily complex cases representative of the routine activity of a catheterisation laboratory. It will be conducted at the Centre Cardiologique du Nord (CCN) in Saint-Denis, France, under the leadership of Mohammed Nejjari, principal investigator, and Franck Digne, co-investigator.
The study will also involve members of Robocath’s medical advisory board (MAB), including Michael Haude (Rheinland Klinikum, Neuss, Germany) and Jean Fajadet (Clinique Pasteur, Toulouse, France), who will provide their clinical and scientific expertise throughout the programme.
“The launch of this first-in-human study represents a major milestone for Robocath. With our second-generation robot we are leveraging the strong clinical and industrial experience acquired with our first platform, now in use internationally. This world first illustrates our leadership position and our commitment to continuing to push the boundaries of interventional robotic technology,” said Philippe Bencteux, president of Robocath.
This clinical launch confirms Robocath’s ambition to further strengthen its global leadership in this market and to contribute sustainably to the evolution of standards of care for patients with coronary artery disease, the company said in a press release.
